Clinical Trial Update: Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

An ongoing Phase I trial is evaluating a combination of rhIL-15, dinutuximab, irinotecan, and temozolomide in children and young adults with relapsed/refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)
• dinutuximab (dinutuximab)
• rhIL-15 (recombinant human interleukin-15)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neuroblastoma | Phase 1 | Status: RECRUITING